Citius Pharma $CTXR Receives “Fast Track” Designation By FDA For Potential $500M Product – Mino-Lok™

Home » CEO Interviews » Citius Pharma $CTXR Receives “Fast Track” Designation By FDA For Potential $500M Product – Mino-Lok™

In this episode, we will be talking to Mr. Myron Holubiak, President and CEO of Citius Pharmaceuticals, ticker CTXR.

Citius is a specialty pharmaceutical company dedicated to the development and commercialization of unique therapeutic products in adjunctive cancer care with a focus on infectious diseases.

Company Highlights

  • Completed $4.1 million private placement; proceeds to be used for product development
    and general working capital
  • Targeting large market opportunities with unmet medical needs with cost-effective products. High growth categories with low developmental risk
  • Highly experienced and successful management team
  • Over $10 million invested by founders; $5 million in public funds
  • Mino-Lok has commenced Phase 3 clinical activities
  • Submitted drug master file to FDA for ethanol component of Mino-Lok
  • In March 2016, Chairman Leonard Mazur invested $3 million for 5 million restricted shares. Equity will be used for development of product portfolio and infrastructure
  • Announced positive results of Phase 2a study for hydrocortisone/lidocaine for hemorrhoids – reformulation underway
  • Multiple near-term milestones

To learn more about them please visit their website at www.citiuspharma.com.

Forward Looking Statements

This CEOLIVE.TV video interview contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company’s current views with respect to future events that involve risks and uncertainties. Among others, these risks include failure to meet schedule or performance requirements of the Company’s contracts, the Company’s ability to raise sufficient development and working capital, the Company’s liquidity position, the Company’s ability to obtain new contracts, the emergence of competitors with greater financial resources, and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur as planned or at all.

Contact CEOLIVE.TV

Mike Elliott
newsdesk@ceolive.tv

Disclaimer

Neither CEOLIVE.TV or any of its principals currently owns or plan to own within 72 hours of publication any shares of the stocks mentioned in this video. For a full disclaimer please visit, ceolive.tv/disclaimer.

CEOLIVE content and productions are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in CEOLIVE content and productions, or other investor relations materials and presentations are subject to change. Neither CEOLIVE nor any of its data or content providers shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. All data and information is provided for informational or entertainment purposes only. CEOLIVE is not a registered broker-dealer or a registered investment advisor.

Get Alerts for Latest Featured Stocks!
Signup today and receive the newest videos. We will never share or sell your email address.
Author: Mike Elliott

Login

Lost your password?